Asunto(s)
Ácido Ascórbico/uso terapéutico , Quemaduras Químicas/tratamiento farmacológico , Quemaduras Químicas/etiología , Tratamiento de Urgencia/métodos , Quemaduras Oculares/inducido químicamente , Quemaduras Oculares/tratamiento farmacológico , Permanganato de Potasio/efectos adversos , Irrigación Terapéutica/métodos , Humanos , Masculino , Persona de Mediana EdadRESUMEN
In psychopharmacological tests in rats and mice, 4-(5-chloro-benzofuranyl-2)-1-methylpiperidine HC1 (CGP 4718 A) was found to exert behavioral effects typical of both monoamine oxidase (MAO)-A and 5-hydroxytryptamine (5-HT) uptake inhibitors (reserpine antagonism, L-5-HTP potentiation, antiaggressive activity in isolated mice). The potential antidepressant activity of the drug was indicated in rats by antagonism of reserpine and its effect in the social-conflict test. CGP 4718 A did not impair motor coordination and had no influence on locomotor activity up to high doses in mice and rats. In monkeys, it increased directed individual activities, including sex-related behaviors and diminished locomotor activity and passivity. Electroencephalographic studies in cats revealed a significant decrease in paradoxical sleep after treatment with CGP 4718 A. In isolated organs, no significant antagonism of norepinephrine, 5-HT, acetylcholine or histamine was found. Cardiovascular studies in cats showed only transient effects on blood pressure and no effect on heart rate. In conscious dogs no cardiovascular effects were found. No potentiation of the pressor effect of tyramine in rats was detectable after repeated doses of up to 300 mg/kg p.o. A weak cardiodepressant effect was seen in isolated guinea pig atria. In conclusion, in animal experiments CGP 4718 A combines an interesting spectrum of antidepressant, activating and antiaggressive properties with a lack of cardiovascular and tyramine-potentiating effects.
Asunto(s)
Antidepresivos/farmacología , Conducta Animal/efectos de los fármacos , Inhibidores de la Monoaminooxidasa/farmacología , Piperidinas/farmacología , Antagonistas de la Serotonina/farmacología , Animales , Gatos , Perros , Interacciones Farmacológicas , Electroencefalografía , Femenino , Cobayas , Hemodinámica/efectos de los fármacos , Técnicas In Vitro , Macaca mulatta , Masculino , Ratones , Ratones Endogámicos , Ratas , Ratas Endogámicas , Especificidad de la EspecieAsunto(s)
Inhibidores de la Monoaminooxidasa/farmacología , Piperidinas/farmacología , Ácido 3,4-Dihidroxifenilacético/metabolismo , Animales , Aminas Biogénicas/metabolismo , Encéfalo/enzimología , Química Encefálica/efectos de los fármacos , Femenino , Hemodinámica/efectos de los fármacos , Ácido Hidroxiindolacético/metabolismo , Hígado/enzimología , Masculino , Metoxihidroxifenilglicol/metabolismo , Ratas , Ratas Endogámicas , Antagonistas de la Serotonina , Sinaptosomas/metabolismo , Tranilcipromina/farmacologíaRESUMEN
Every varicosis can be treated without operation if injection therapy is correctly carried out. The patient stands upright, a thick needle (1.2 mm) is inserted into the varix. The venous blood flows out, the patient lies down. Injection is made with the leg in a high position (30 degrees), compression follows each sclerosing injection. Intraarterial injections can be avoided by using a thick needle. Retained intravaricose blood should be incised to avoid pigmentation. Rapid treatment is possible with 3-5 days. As with our ordinary treatment, we give 5-10 injections daily with Varigloban 2-8%.